Eli Lilly price target lowered to $973 from $995 at Guggenheim
Guggenheim lowered the firm’s price target on Eli Lilly (LLY) to $973 from $995 and keeps a Buy rating on the shares. The firm is updating its ...
Hims & Hers Health down 3% after BoA says Q4 revenue could be a miss
Hims & Hers Health is down ~3% in Friday morning trading after an analyst note from BofA Securities stated that the company's ...
Leerink keeps Eli Lilly stock outperform on revenue growth
Leerink Partners maintained a positive outlook on shares of Eli Lilly and Company (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $950.00. The pharmaceutical giant, currently ...
US open: Stocks higher going into MLK Day long weekend
On the macro front, building permits decreased by 0.7% month-on-month in December to a seasonally adjusted rate of 1.48m, ...
JPM 2025: WuXi AppTec rebuffs concern about lower GLP-1 demand after Lilly’s low revenue forecast
Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.
Intuitive Surgical: Strong Financial Performance and Market Position Justify Buy Rating
Leerink Partners analyst Mike Kratky has maintained their bullish stance on ISRG stock, giving a Buy rating yesterday.Stay Ahead of the ...
Trump Treasury pick Bessent backs tax cuts, tariffs
STORY: Donald Trump's pick for Treasury secretary, Scott Bessent, on Thursday said the U.S. dollar should remain the world's ...